Novartis has reported positive top-line results from the Phase III CANTOS clinical trial of ACZ885 (canakinumab) and standard-of-care combination to address cardiovascular risk in patients who survived a heart attack.

ACZ885 is a high-affinity, selective, fully human monoclonal antibody currently being developed to inhibit inflammation by blocking the action of a cytokine called IL-1ß.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The results showed that the drug met the primary endpoint by decreasing cardiovascular risk in people with a history of heart attack and inflammatory atherosclerosis.

Novartis drug development global head and chief medical officer Vas Narasimhan said: "Despite current treatment, about 25% of heart attack survivors will have another cardiovascular event within five years, making the outcome of the CANTOS study a promising new development for patients.

"ACZ885 is the first and only investigational agent that has shown that selectively targeting inflammation reduces cardiovascular risk."

"ACZ885 is the first and only investigational agent that has shown that selectively targeting inflammation reduces cardiovascular risk.”

See Also:

The randomised, double-blind, placebo-controlled, event-driven Phase III Canakinumab anti-inflammatory thrombosis outcomes study (CANTOS) assessed the efficacy, safety and tolerability of quarterly subcutaneous ACZ885 over six years in 10,061 subjects with previous myocardial infarction (MI).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial’s primary endpoint was a decrease in the risk of major adverse cardiovascular events (MACE), a composite of cardiovascular death, non-fatal MI and non-fatal stroke.

Secondary endpoints such as time to first occurrence of the composite CV endpoint, time to new onset type 2 diabetes in patients with pre-diabetes at the time of enrolment, time to occurrence of non-fatal MI, non-fatal stroke or all-cause mortality and time to all-cause mortality were also investigated.